Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma

Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma

Lenvatinib is a multitarget tyrosine kinase inhibitor (TKI) approved for the treatment of several types of cancers, including metastatic differentiated thyroid cancer (DTC). The intended targets include VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT signaling pathways, but drug resistance inevitably deve...

Full description

Bibliographic Details
Main Authors: Chunying Peng, Katrin Rabold, Mihai G. Netea, Martin Jaeger, Romana T. Netea-Maier
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Pharmaceutics
Subjects:
tyrosine kinase inhibitors
innate immunity
thyroid cancer
tumor-associated macrophages
cytokines
Online Access:https://www.mdpi.com/1999-4923/15/2/412

Internet

https://www.mdpi.com/1999-4923/15/2/412

Similar Items